Menu
GWAS Study

Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects.

Roberts GHL, Partha R, Rhead B et al.

35410379 PubMed ID
GWAS Study Type
100400 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RG
Roberts GHL
PR
Partha R
RB
Rhead B
KS
Knight SC
PD
Park DS
CM
Coignet MV
ZM
Zhang M
BN
Berkowitz N
TD
Turrisini DA
GM
Gaddis M
MS
McCurdy SR
PM
Pavlovic M
RL
Ruiz L
SC
Sass C
HB
Haug Baltzell AK
GH
Guturu H
GA
Girshick AR
BC
Ball CA
HE
Hong EL
RK
Rand KA
Chapter II

Abstract

Summary of the research findings

Multiple COVID-19 genome-wide association studies (GWASs) have identified reproducible genetic associations indicating that there is a genetic component to susceptibility and severity risk. To complement these studies, we collected deep coronavirus disease 2019 (COVID-19) phenotype data from a survey of 736,723 AncestryDNA research participants. With these data, we defined eight phenotypes related to COVID-19 outcomes: four phenotypes that align with previously studied COVID-19 definitions and four 'expanded' phenotypes that focus on susceptibility given exposure, mild clinical manifestations and an aggregate score of symptom severity. We performed a replication analysis of 12 previously reported COVID-19 genetic associations with all eight phenotypes in a trans-ancestry meta-analysis of AncestryDNA research participants. In this analysis, we show distinct patterns of association at the 12 loci with the eight outcomes that we assessed. We also performed a genome-wide discovery analysis of all eight phenotypes, which did not yield new genome-wide significant loci but did suggest that three of the four 'expanded' COVID-19 phenotypes have enhanced power to capture protective genetic associations relative to the previously studied phenotypes. Thus, we conclude that continued large-scale ascertainment of deep COVID-19 phenotype data would likely represent a boon for COVID-19 therapeutic target identification.

3,742 European ancestry cases, 79,430 European ancestry controls, 1,118 Hispanic or Latin American cases, 10,349 Hispanic or Latin American controls, 513 African American or Afro-Caribbean cases, 5,248 African American or Afro-Caribbean controls

Chapter III

Study Statistics

Key metrics and study information

100400
Total Participants
GWAS
Study Type
No
Replicated
European, Hispanic or Latin American, African American or Afro-Caribbean
Ancestry
U.S.
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.